eHealth Ventures is happy to announce an investment in VocaVibe – a voice-based, AI-driven system for supporting the diagnosis and monitoring of neurodegenerative diseases. The patient’s voice will undergo processing and analysis using AI models, which will provide physicians with valuable information regarding disease diagnosis, monitoring, staging, and the effects of the medical and behavioral treatments.
This innovative approach addresses a pressing unmet need in the field of healthcare just imagine – a loved one speaks on the phone and his/her voice is an accurate marker for diagnosis and for staging a disease, as well as monitoring the effectiveness of the treatment!
By using a short voice sample provided over the phone or in person, the company will be able to accurately assess the stage and condition of neurological diseases such as Dementia, Alzheimer’s, and Parkinson’s. Additionally, it can provide valuable insights to physicians regarding disease management.
The groundbreaking idea behind VocaVibe originated in a pilot study conducted at the Tel Aviv Souraski Medical Center (Ichilov, Tel-Aviv).
The co-founder and CEO of VocaVibe is Dr. Ariel Schiff, MD, MPH, MBA, who commented: “we are very excited to receive an investment from one of the leading digital health partnerships in Israel, with a proven track record, a powerful list of partners and a highly experienced team. I am sure we will prove the technological and clinical efficacy of our groundbreaking solution and move aggressively towards commercialization”.
For more details:
*Image by Gordon Johnson from Pixabay
About eHealth Ventures
The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).
